About Izana bioscience

About company

Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market. Izana Bioscience are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF). IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.